Delezé M, Alarcón-Segovia D, Oria C V, Sánchez-Guerrero J, Fernández-Dominguez L, Gomez-Pacheco L, Ponce de León S
Department of Immunology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico.
J Rheumatol. 1989 Jul;16(7):926-30.
We studied 500 consecutive patients with systemic lupus erythematosus (SLE) for antibodies to phospholipids (APLA) by an ELISA method using cardiolipin as antigen and antiimmunoglobulins G, M and A to determine their isotype. Once entered into this prospective study the patients were followed for up to 16 months (mean 7.7 +/- 4.72 SD) with periodic determinations of APLA. Of the 500 patients with SLE, 88 had had thrombocytopenia, 25 had had hemolytic anemia, 25 had had both, and 362 had no history of these hemocytopenias. If we considered the odds ratio of these 362 patients for having high titer APLA as 1, patients with a history of thrombocytopenia, hemolytic anemia or both had significantly higher odds ratios of having APLA than did those without hemocytopenia. Patients with thrombocytopenia had significantly higher levels of IgG APLA, those with hemolytic anemia had significantly higher titers of IgM APLA and patients with both had significantly higher titers of both of these APLA isotypes, than did patients without hemocytopenias. A correlation between positive direct Coombs' tests and IgM APLA was also found. We conclude that APLA is associated with these hemocytopenias in SLE. This might be due to their interaction with negatively charged phospholipids in the cell walls of the respective cells.
我们采用以心磷脂为抗原的酶联免疫吸附测定(ELISA)方法,研究了500例系统性红斑狼疮(SLE)患者的抗磷脂抗体(APLA),并使用抗免疫球蛋白G、M和A来确定其同种型。一旦进入这项前瞻性研究,患者将被随访长达16个月(平均7.7±4.72标准差),并定期测定APLA。在500例SLE患者中,88例有血小板减少症,25例有溶血性贫血,25例两者都有,362例无这些血细胞减少症病史。如果将这362例患者出现高滴度APLA的优势比视为1,有血小板减少症、溶血性贫血或两者都有的患者出现APLA的优势比显著高于无血细胞减少症的患者。有血小板减少症的患者IgG型APLA水平显著更高,有溶血性贫血的患者IgM型APLA滴度显著更高,两者都有的患者这两种APLA同种型的滴度均显著更高,高于无血细胞减少症的患者。还发现直接抗人球蛋白试验阳性与IgM型APLA之间存在相关性。我们得出结论,APLA与SLE中的这些血细胞减少症相关。这可能是由于它们与各自细胞细胞壁中带负电荷的磷脂相互作用所致。